# Topical Sirolimus in Cutaneous Lymphatic Malformations

> **NCT03972592** · PHASE2 · COMPLETED · sponsor: **University Hospital, Tours** · enrollment: 55 (actual)

## Conditions studied

- Vascular Malformations
- Lymphatic Malformation

## Interventions

- **DRUG:** Topical 0.1% Sirolimus
- **DRUG:** Topical Vehicle

## Key facts

- **NCT ID:** NCT03972592
- **Lead sponsor:** University Hospital, Tours
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-05
- **Primary completion:** 2024-08-14
- **Final completion:** 2024-08-14
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03972592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03972592, "Topical Sirolimus in Cutaneous Lymphatic Malformations". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03972592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*